18Dec/25
The Era of the “Biological Missile”: Innovations and Frontiers in Antibody-Drug Conjugate Development
In the rapidly evolving landscape of oncology, Antibody-Drug Conjugates (ADCs) have emerged as one of the most promising classes of therapeutics. Often described as “biological missiles,” these sophisticated molecules represent a preciseRead More…